Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Metformin

"* Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"

DRUG

HMS5552

"* Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~* HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."

Trial Locations (1)

07601

Frontage Clinical Services Inc., Hackensack

Sponsors
All Listed Sponsors
lead

Hua Medicine Limited

INDUSTRY

NCT02597400 - Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM | Biotech Hunter | Biotech Hunter